Epidemiology, antibiotic consumption and molecular characterisation of Staphylococcus aureus infections – data from the Polish Neonatology Surveillance Network, 2009–2012

Table 2 Distribution of individual antibiotic groups usage in MRSA (18 cases) and MSSA (28 cases) infections

Antibiotic groups	DOT [%]		OR (95%CI) P-value	DDD [%]		OR (95%CI) P-value
Antibiotic groups	MRSA	MSSA	OR (95%CI) P-value	MRSA	MSSA	OR (95%CI) P-value
Aminoglycosides	17.2	14.9	0.976 (0.697–1.367) 0.967	31.7	28.0	1.366 (1.096–1.704) 0.561
Beta-lactams	6.3	31.7	0.146 (0.092–0.233) 0.005	19.0	40.9	0.338 (0.264–0.435) 0.879
Fluoroquinolones	6.0	0.0	n/a	9.3	0.0	n/a
Glycopeptides	63.6	43.0	2.296 (1.766–2.985) 0.427	33.4	24.9	1.513 (1.208–1.895) 0.533
Lincozamides	2.7	1.1	2.562 (1.008–6.512) 0.221	0.8	1.0	0.775 (0.250–2.408) 0.073
Macrolides	4.2	5.8	0.723 (0.393–1.330) 0.832	2.8	4.4	0.629 (0.348–1.138) 0.072
Trimethoprim/sulfamethoxazole	0.0	3.0	n/a	0.0	0.2	n/a
Metronidazole	0.0	0.5	n/a	0.0	0.6	n/a
Total	100.0	100.0		100.0	100.0

OR, odds ratio; 95%CI, 95% Confidence Interval; DOT, the aggregate sum of the number of days during which at least 1 dose of antibiotic was received for each one received, days of treatment; DDD, defined daily dose expressed in days; n/a not applicable.

ISSN: 1471-2334